Second, CXCR4 antagonists could inhibit the activation of the signaling axis and therefore restrain the invasive potency and tumorigenicity of GEM-R PaCa cells. The gene discussed is CXCR4; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.